processes

Supplementary Files: Food-Derived Bioactive Peptides with Antioxidative Capacity, Xanthine Oxidase and Tyrosinase Inhibitory Activity

Anthony Thaha [1], Bor-Sen Wang [2], Yu-Wei Chang [1,3], Shih-Min Hsia [4], Tsui-Chin Huang [5], Chyuan-Yuan Shiau [1], Deng-Fwu Hwang [1] and Tai-Yuan Chen [1,*]

[1] Department of Food Science, Center of Excellence for the Oceans, National Taiwan Ocean University, Keelung 20224, Taiwan; anthonythaha@gmail.com (A.T.); bweichang@email.ntou.edu.tw (Y.-W.C.); cyshiau@mail.ntou.edu.tw (C.-Y.S.); dfhwang@mail.ntou.edu.tw (D.-F.H.)
[2] Department of Applied Life Science & Health, Chia-Nan University of Pharmacy and Science, Tainan 71710, Taiwan; wangbs@mail.cnu.edu.tw
[3] Institute of Food Safety and Risk Management, National Taiwan Ocean University, Keelung 20224, Taiwan
[4] School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 11031, Taiwan
[5] Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
* Correspondence: tychen@email.ntou.edu.tw; Tel: +886-2-24622192 (ext.5124); Fax: +886-2-24628750




Figure S1. Michaelis-Menten model of chosen bioactive peptides; i.e. VW4 (VWWW, Peptide 2), IW3 (IRW, Peptide 3), and VS14 (VKAGFAWTANQQLS, Peptide 9); against allopurinol as positive control and control for xanthine oxidase inhibition assay. The concentration of peptide used was 1 mg/mL, while concentration of allopurinol was 0.1 mg/mL. Data expressed as means ± SD of triplicates.




Figure S2. (**a**) Lineweaver-Burk model of allopurinol as positive control against control for xanthine oxidase inhibition assay. (**b**) The plot in squared area (from 0.0 mM^{-1}–1.0 mM^{-1} Xanthine) is exhibited at higher magnification.




Figure S3. (**a**) Lineweaver-Burk model of VW4 against control for xanthine oxidase inhibition assay. (**b**) The plot in squared area (from 0.0 mM^{-1}–1.0 mM^{-1} Xanthine) is exhibited at higher magnification.




Figure S4. (**a**) Lineweaver-Burk model of IW3 against control for xanthine oxidase inhibition assay. (**b**) The plot in squared area (from 0.0 mM^{-1}–1.0 mM^{-1} Xanthine) is exhibited at higher magnification.




Figure S5. (**a**) Lineweaver-Burk model of VS14 against control for xanthine oxidase inhibition assay. (**b**) The plot in squared area (from 0.0 mM^{-1}–1.0 mM^{-1} Xanthine) is exhibited at higher magnification.




Figure S6. Michaelis-Menten model of chosen bioactive peptides; i.e. VW4 (peptide 2), IW3 (peptide 3), and VS14 (peptide 9); against control for tyrosinase inhibition assay. The concentration of peptide used was 0.5 mg/mL. Data expressed as means ± SD of triplicates.




Figure S7. (**a**) Lineweaver-Burk model of VW4 against control for tyrosinase inhibition assay. (**b**) The plot in squared area (from 0.0 mM^{-1}–2.0 mM^{-1} L-tyrosine) is exhibited at higher magnification.




Figure S8. (**a**) Lineweaver-Burk model of IW3 against control for tyrosinase inhibition assay. (**b**) The plot in squared area (from 0.0 mM^{-1}–2.0 mM^{-1} L-tyrosine) is exhibited at higher magnification.




Figure S9. (**a**) Lineweaver-Burk model of VS14 against control for tyrosinase inhibition assay. (**b**) The plot in squared area (from 0.0 mM^{-1}–2.0 mM^{-1} L-tyrosin) is exhibited at higher magnification.